Overview
Novel regulatory molecules in tumor immunity and cancer immunotherapy
The traditional cancer therapy is organ- and tissue-based, which has been ineffective in terms of cure rate, and which also frequently leads to therapy resistance and disease relapse. Recently, more common genetic features across cancer types are beginning to come to light by extensive genomic information now available on tumors. A new paradigm is thus emerging that combinations of a few key mutations in critical biological pathways may underlie broad arrays of malignant development and aggression. Targeting these common and vital points of tumorigenic regulation may yield much greater impact on cancer therapy across the spectrum than aiming at narrowly focused, individual cancer specific targets, if systemic toxicity can be avoided. Our recent clinical and laboratory investigations have identified UBR5, a novel HECT domain E3 ubiquitin ligase of fundamental importance, as an essential cross-cancer regulator of tumorigenesis and anti-tumor immunity. UBR5 gene alterations (predominantly amplifications and overexpression) occur in ~45% of prostate cancer, 25-35% of breast and ovarian cancers, close to 20% of bladder, liver, uterine, and stomach cancers, and in 10% of many other types of solid tumors. In addition, genetic lesions in UBR5 have been found strongly associated with reduced survival of breast, ovarian, prostate, and pancreatic cancer patients. Yet, how UBR5 promotes cancer progression is highly obscure. We and our collaborators are using state of the art technologies, unconventional and creative experimental strategies to explore the pathophysiology and immunobiology of this mysterious molecule of great clinical potentials. We are exploring UBR5’s immunological role and identify “neoantigens” induced in UBR5-targeted tumors that may trigger T cell responses for prospective cancer vaccine development and immunotherapy. Targeting the UBR5 pathway will not only bring immediate clinical benefits to patients of a wide array of highly aggressive and therapy-resistant malignancies by abrogating cancer growth and metastasis, but also lead to immune activation that will result in the generation of T cell memories and delicate immunosurveillance against cancer recurrence and drug resistance.
Highlights
- 1
- 2International journal of cancer · 2023
- 3
Publications
Funding
Active
4 grants- KPHT9425-26-1-E178Pharmacological Targeting of UBR5 for Breast Cancer ImmunotherapyU.S. Department of Defense · 2026–2029
- PIHT9425-26-1-E177Pharmacological Targeting of UBR5 for Breast Cancer ImmunotherapyU.S. Department of Defense · 2026–2029
- Co-IR01CA276053-03Novel proteasome inhibitors targeting both beta5 and beta2 subunits for treatment of triple negative breast cancerNational Cancer Institute · 2024–2028
- MPIR01CA273716-04UBR5's Mechanisms of Action in Tumorigenesis and ImmunoregulationNational Cancer Institute · 2023–2028
Completed grants (20)
- PIWRCG 241123-01Targeting UBR5 with a Novel PROTAC in Glioblastoma ModelsWilliam Rhodes Center for Glioblastoma - Collaborative Research Initiative · 2023–2025
- PIW81XWH-21-1-0261Investigation of UBR5 and its signaling as a novel target for breast cancer therapyU.S. Department of Defense · 2021–2025
- PISeed Grant 241580-01Computationally designed protein degraders targeting a proto-oncoprotein for cancer therapyCornell University - Ithaca · 2024–2024
- Co-INPRP12S-0317-190379UBR5, E3 Ubiquitin Ligase, in Triple Negative Breast Cancers: Potential Role in Anti-Tumor Immunity and Cancer MetabolismQatar National Research Fund · 2020–2024
- Sub-PINPRP-S 12-0317-190379UBR5, E3 Ubiquitin Ligase, in Triple Negative Breast Cancers: Potential Role in Anti-Tumor Immunity and Cancer MetaboQatar National Research Fund · 2020–2024 · via Weill Cornell Medical College/Qatar
- PIR03CA230573-02Investigation of EDD's Extraordinary Tumorigenic ActivitiesNational Cancer Institute · 2018–2021
- PIMSKCC 211192-01Functional investigation of a hotspot mutation in UBR5-driven cancersMemorial Sloan Kettering Cancer Center · 2020–2021ContractNo publications yet
- PITri-I TDI 204123-01UBR5 degradation via PROTACs for cancer therapyTri-Institutional Therapeutics Discovery Institute, Inc. · 2020–2021Contract
- PIDFI 180106-02In Search of an Inhibitor of the E3 Ubiquitin Ligase UBR5 for Cancer TherapyDaedalus Fund for Innovation (Weill Cornell) · 2017–2020
- PICU 202745-01Understanding the physical basis of the profound role of UBR5 in breast cancer metastasisCornell University - Ithaca · 2020–2020
- Sub-PINY NPRP 7-136-3-031Aggressive Breast Cancers in Arab Populations: CCL5 Implications as a Potential Target for Breast Cancer TherapyQatar National Research Fund · 2015–2019 · via Weill Cornell Medical College/Qatar
- PIR21AI110815-02Role of Two Novel Genes in IL-23 Production and Th17-Mediated Pathogenesis in SLENational Institute of Allergy and Infectious Diseases · 2014–2017
- PIR56AI103157-01A1EMechanism of Progranulin-Mediated Control of Septic Inflammation via IL-10National Institute of Allergy and Infectious Diseases · 2014–2016
- KPR01AI083219-05Immunochemotherapy in Visceral LeishmaniasisNational Institute of Allergy and Infectious Diseases · 2010–2016
- PIR56AI095512-01EWORegulation of IL-10 Gene Expression and Host Septic Response by ProgranulinNational Institute of Allergy and Infectious Diseases · 2011–2013
- PIR01AI072149-02 EWCrohn's Disease-Associated NOD2 MutantsNational Institute of Allergy and Infectious Diseases · 2009–2011
- PIR21AT004349-02Mechanism of Modulation of Interleukin-12 Production by TriptolideNCCIH · 2007–2010 · via NIH RePORTER
- PIR01AI045899-11Cytokine Production In Phagocytosis of Apoptotic CellsNIAID · 1999–2010 · via NIH RePORTER
- PIR01CA100223-05Regulation of IL-12 Expression and Activity by OncogenesNCI · 2004–2010 · via NIH RePORTER
- PIK01CA079772-05MOLECULAR REGULATION OF INTERLEUKIN 12 GENE EXPRESSIONNCI · 1999–2004 · via NIH RePORTER
News mentions
- $2.5 Million Department of Defense Grant Funds Development of Targeted Therapy for Triple-Negative Breast CancerJuly 16, 2026
Weill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers.
- Protein Found in Aggressive Ovarian Cancers Promotes Tumor Growth by Bringing In Protective Immune CellsDecember 11, 2020
Ovarian tumors can be made more sensitive to immunotherapy by blocking the recruitment of certain cells to the area surrounding the cancer, according to preclinical research by investigators at Weill Cornell Medicine. Unlike some other solid tumors, including lung cancer and melanoma, ovarian cancer generally does not respond to immunotherapy. In a study published Dec. 8 in Nature Communications, researchers looked at the role of a protein called UBR5, which is found at high levels, or amplified, in particularly aggressive cases of ovarian cancer. They found that UBR5 draws in immune cells called macrophages to the area around the tumor known as the tumor microenvironment, which protect the cancer cells. Furthermore, when they blocked UBR5 in tumors in animal models, they were able to destroy previously resistant tumors with two different forms of immunotherapy as well as chemotherapy. “Clinical data show that amplification of UBR5 in the tumor is associated with significantly shorter survival times in patients with ovarian cancer,” said senior author Dr. Xiaojing Ma, professor of microbiology and immunology and of microbiology and immunology in pediatrics. “Our studies in the lab found that this is the case because UBR5 allows the cancer cells to send out signals that bring in macrophages. These macrophages, in turn, promote cancer growth and spread by providing essential nourishment and suppressing the immune system.” In earlier work, Dr. Ma and his team identified UBR5 as an important factor in making triple negative breast cancers more aggressive. (Triple-negative breast cancers lack a receptor called HER2 and receptors for estrogen and progesterone, three factors that can be targeted with drugs.) In animals that had no immune systems, higher levels of UBR5 did not affect the aggressiveness of the cancer, suggesting that UBR5 was acting through the immune system. In the case of breast cancer, the researchers found that UBR5 inhibits the activation of immune…
Media highlights
- Department Of Defense Grant Funds Development of Targeted Therapy For Triple-Negative Breast CancerOncology Times · September 1, 2026
Mentoring
- JLJingwen LiuPostdoc mentee · 2024–2024